Skip to main content
Erschienen in: Medical Oncology 4/2014

01.04.2014 | Letter to the Editor

Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer

verfasst von: Mingming Wang, Lin Shen, Dajun Deng

Erschienen in: Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Excerpt

Aberrant methylation of CHFR (Checkpoint with forkhead associated and ring finger) gene was frequently happened in cancer and had been reported to be associated with the sensitivity of microtubule inhibitors in several cancer cells containing gastric cancer cells in vitro experiments [1]. However, the clinical significance of CHFR methylation and chemosensitivity of microtubule inhibitors (paclitaxel or docetaxel) in gastric cancer patients was investigated only in few studies with limited samples, and the conclusion was controversial [2, 3]. In this study, we aimed to investigate the association between CHFR methylation and the sensitivity of paclitaxel in Chinese advanced gastric cancer (AGC) patients to identify the potential predictor of paclitaxel. …
Literatur
1.
Zurück zum Zitat Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 2013. Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 2013.
2.
Zurück zum Zitat Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol. 2006;41(2):133–9.PubMedCrossRef Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol. 2006;41(2):133–9.PubMedCrossRef
3.
Zurück zum Zitat Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, Yasui W. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Res. 2006;26(1A):49–54.PubMed Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, Yasui W. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Res. 2006;26(1A):49–54.PubMed
Metadaten
Titel
Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer
verfasst von
Mingming Wang
Lin Shen
Dajun Deng
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0907-6

Weitere Artikel der Ausgabe 4/2014

Medical Oncology 4/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.